Drug Trial Radar · NCT04311671
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,979
Actual
Start
May 3, 2021
Primary completion
Sep 27, 2024
Study completion Sep 27, 2024
Sponsor
- Lead sponsor
- Medicines Development for Global HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.
Conditions
- Onchocerciasis
Interventions
MoxidectinDrug
2 mg tablets, encapsulated for blinding
IvermectinDrug
3 mg tablets, encapsulated for blinding
AlbendazoleDrug
400 mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment Emergent Adverse EventsTime frame: Up to 3 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire
Abidjan, Côte d’Ivoire
Centre de Recherche pour les Maladies Tropicales Negligees
Rethy, Ituri, Democratic Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.